New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
07:25 EDTAGN, SNY, JNJ, GSK, NVSAllergan rejected by rivals Sanofi, J&J as it looks for offers, Bloomberg says
Allergan (AGN) has so far been has so far been rejected by rival companies, which include Sanofi (SNY) and Johnson & Johnson (JNJ), as it has aims to entice firms to make a competing bid, according to Bloomberg, citing people familiar with the matter. One source said that Allergan also contacted GlaxoSmithKline (GSK) and Novartis (NVS). Reference Link
News For AGN;SNY;JNJ;GSK;NVS From The Last 14 Days
Check below for free stories on AGN;SNY;JNJ;GSK;NVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
August 20, 2014
08:29 EDTGSKPernix Therapeutics to host conference call
Conference call to discuss acquisition of Treximet will be held on August 20 at 9 am. Webcast Link
08:04 EDTGSKPOZEN announces U.S. rights for Treximet acquired by Pernix Therapeutics
Subscribe for More Information
07:19 EDTAGNPossible Allergan Salix deal could be 8% accretive in '15-'16, says Wells Fargo
After The Wall Street Journal reported that Allergan (AGN) had approached Salix (SLXP) and other companies about a potential acquisition, Wells Fargo thinks that a largely debt financed purchase of Salix could be 8% accretive for Allergan in 2015-2016, reaching 12% accretion in 2018.
07:07 EDTAGNSome Valeant shareholders express uncertainty over Allergan deal, Reuters says
Subscribe for More Information
07:04 EDTAGNSalix buyout price could be near $192 per share, says William Blair
William Blair believes a combined Allergan (AGN) and Salix (SLXP) would be very attractive. The firm estimates a potential takeover price for Salix towards the high end of its $176-$192 per share range. Salix rose 16% yesterday to $160.80 after Wall Street Journal reported that Allergan approached the company and at least one other about a takeover.
05:17 EDTNVSNovartis provides drug candidate compounds to TB Alliance
Subscribe for More Information
August 19, 2014
17:14 EDTAGNOn The Fly: Closing Wrap
Subscribe for More Information
16:52 EDTAGNAllergan all-cash deal would reduce hostile bid chances, says BMO Capital
Subscribe for More Information
16:46 EDTSNYFDA approves Genzyme Cerdelga capsules
Subscribe for More Information
14:40 EDTAGNSterne Agee says Allergan could pay up to $190 for Salix and still be accretive
Subscribe for More Information
13:13 EDTAGNAllergan approached Salix, one other about takeover, WSJ reports
Subscribe for More Information
13:06 EDTAGNSalix jumps 6% to $147.85 after WSJ report of Allergan approach
Subscribe for More Information
13:05 EDTAGNAllergan approached Salix about takeover, WSJ reports
05:11 EDTNVSGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information
August 18, 2014
15:59 EDTAGNAllergan CFO change may suggest strategic deal near, says BMO Capital
BMO Capital believes former Allergan (AGN) CFO Jeff Edwards would not be leaving if a change of control of the company, such as a takeover by Valeant (VRX), were in the future. Rather, BMO thinks Edwards' decision to leave could be a sign that a strategic transaction marking a new chapter in Allergan's growth may be nearing. The firm thinks Allergan is in capable hands with new CFO Jim Hindman and it keeps an Outperform rating on the stock with a $230 price target.
11:57 EDTAGNAllergan CFO departure largely unexpected, says Wells Fargo
Subscribe for More Information
11:41 EDTJNJCubist rises after report sparks takeover interest speculation
Subscribe for More Information
09:02 EDTAGNAllergan names Jim Hindman as CFO, effective immediately
Subscribe for More Information
07:57 EDTAGNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
07:35 EDTNVSApricus Biosciences launches topical ED treatment in Germany
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use